Previously defined thresholds for total testosterone (TT) concentrations to screen for androgenproducing tumors (APTs) have used RIA, which can be less accurate in women. We aimed to define diagnostic thresholds to screen for APTs or postmenopausal pathologic hyperandrogenism using TT concentrations measured by LC-MS/MS.
The prevalence of hirsutism has been estimated to be as high as 8% in women in the US (1 ) . The evaluation of hirsutism often includes measurement of serum total testosterone (TT) 3 concentrations to determine the need to screen for androgen-producing tumors (APTs). A recent update to the Endocrine Society guidelines recommends measurement of circulating TT concentrations in all women presenting with hirsutism for the diagnosis of polycystic ovary syndrome (PCOS) and to screen for APTs (2 ) . The inclusion of all women presenting with hirsutism extends TT evaluation to as many as an estimated 8% to 20% women with PCOS in the US (1, 3 ) . Although APTs are rare (considered the cause of androgen excess in Ͻ1% of women), identification and surgical resection of an APT could have a major clinical impact leading to rapid resolution of symptoms (4 ) . In postmenopausal women, ovarian hyperthecosis (a nonneoplastic process) can mimic an APT, presenting with severe hyperandrogenism (5 ) . Oophorectomy for ovarian hyperthecosis can result in rapid resolution of symptoms. A TT threshold for pathologic hyperandrogenism in postmenopausal women has not been previously defined and would require separate analysis because of the substantial decline in ovarian androgen production after menopause (6 ) .
Previously defined discriminatory thresholds have ranged from 5.2 to 6.9 nmol/L for APTs (7) (8) (9) . How-ever, these recommendations were based on measurement of TT by RIA, which is less accurate in women than men, who have concentrations 10-fold higher than women (10, 11 ) . In addition, individual laboratory methods can influence intraassay variability substantially when immunoassay kits are used (12 ) . Liquid chromatography-mass spectrometry (LC-MS/MS) has the potential to provide specific and accurate measurement of TT concentrations and is being standardized in conjunction with the CDC (13, 14 ) . Indeed, measurements of sex steroids in children and women by mass spectrometry are being recommended for use in research studies owing to the inaccuracy of RIA at lower concentrations and anticipation that sex steroid hormones will soon be clinically measured exclusively by mass spectrometry (15 ) . Data on the appropriate LC-MS/MS TT threshold for further evaluation for an APT or pathologic cause of hyperandrogenism are needed and have not been previously evaluated.
In the current project, we studied a large group of women with presentation of severe biochemical hyperandrogenemia (often presenting a dilemma for clinicians in practice) over a 10-year period beginning in 2004 when Ͼ14000 TT measurements were made by LC-MS/MS. Our overall aim was to identify the optimal discriminatory threshold for APT. In addition, we performed a secondary analysis that included all postmenopausal women presenting with symptoms or signs of hyperandrogenism during the same period to define a diagnostic threshold specific to the diagnosis of pathologic hyperandrogenism (both APT and ovarian hyperthecosis) in postmenopausal women. We hypothesized that the diagnostic TT threshold for APT and postmenopausal pathologic hyperandrogenism as measured by LC-MS/MS would be lower than the threshold previously referenced with RIA, and that the diagnostic threshold for postmenopausal pathologic hyperandrogenism would be even lower than for APT.
Materials and Methods

PARTICIPANTS
This is a retrospective cohort study of (a) all women with severe biochemical hyperandrogenemia and (b) postmenopausal women presenting with new symptoms of hyperandrogenism at the Mayo Clinic in Rochester, MN, from January 1, 2004, to December 31, 2014. The initial dates of search coincided with exclusive use of LC-MS/MS assay in the Mayo laboratories for measurement of serum TT. After receiving Institutional Review Board committee approval, we identified cases by using an institutional clinical data repository query tool (Advanced Cohort Explorer) that rapidly searches text within laboratory results and all aspects of clinical notes (e.g., laboratory, radiology, and pathology notes) in the electronic health record at the Mayo Clinic (Rochester, MN).
For the first cohort, we identified all women with a serum TT concentration of Ն3.5 nmol/L. A second postmenopausal cohort was created including all women with documentation in their clinical notes of postmenopausal status, symptoms or signs of hyperandrogenism (hirsutism, hyperandrogenism, or clitoromegaly), and a measured serum TT. Demographic, clinical, and laboratory data, imaging characteristics, and pathological diagnoses were collected.
DIAGNOSTIC CRITERIA AND GROUP DEFINITIONS
PCOS was assigned as the final diagnosis if the woman was premenopausal and there was clinical documentation of PCOS (based on the Rotterdam criteria: presence of at least 2 of the following: oligo/anovulation, clinical or biochemical evidence of hyperandrogenism and/or polycystic ovary morphology on ultrasound without other secondary causes of androgen excess and/or oligo/ anovulation) ( Table 1 ) (16 ) . In this cohort, postmenopausal hyperandrogenism was defined as postmenopausal women with biochemical hyperandrogenism but without an APT. Postmenopausal status was confirmed in the clinical notes by Ն1 year after the final menstrual period or history of bilateral oophorectomy. The diagnosis of APT required a radiologic image identifying a tumor, ovarian venous sampling localizing the source from 1 organ (1 adrenal or 1 ovary), or the pathologic diagnosis of tumor.
In the postmenopausal cohort with hyperandrogenism, postmenopausal pathologic hyperandrogenism included women diagnosed with APT or ovarian hyperthecosis for the objective of defining a screening threshold for further diagnostic testing. Ovarian hyperthecosis was diagnosed by pathologic confirmation of stromal hyperplasia without a tumor present, resolution of hyperandrogenism after bilateral oophorectomy without a tumor identified by pathology or after medical ovarian suppression, or clinical diagnosis based on radiologic enlargement of both ovaries (Ͼ4 cm 3 ) (17 ), significant virilization or progressive pace of symptoms or unilateral ovarian enlargement without identification of a tumor, or increased TT in both ovarian veins on ovarian vein sampling. Idiopathic hyperandrogenism was defined as TT in the reference interval (Ͻ2.1 nmol/L) and/or mild nonprogressive hirsutism and/or previous premenopausal diagnosis of PCOS.
Participants were excluded if they had no clinical evaluation in the electronic health record, were receiving exogenous testosterone replacement, or were transgender, pregnant, Ͻ18 years old, or had another diagnosis that could influence TT concentrations (e.g., cirrhotic liver disease, adrenocortical carcinoma, Cushing's disease/syndrome, congenital adrenal hyperplasia, or andro-gen insensitivity syndrome) (Fig. 1) . Fifty-three women in the second cohort were excluded owing to lack of documented symptoms of hyperandrogenism. In other words, phrases such as "no hirsutism" or "denies symptoms of hyperandrogenism" were used in their clinical chart (Fig. 1B) .
ANALYTIC TECHNIQUES
TT was measured via extraction utilizing high-throughput liquid chromatography followed by conventional liquid chromatography and analysis on a tandem mass spectrometer (LC-MS/MS) (18 ) . Intraassay and interassay CVs were Ͻ5%. Bioavailable testosterone was measured using an isotopic precipitation method. After precipitation, radioactivity was measured in the supernatant; the bioavailable testosterone results were expressed as a percentage of total testosterone (19 ) . Free testosterone was measured via equilibrium dialysis of free-labeled testosterone through a semipermeable membrane to separate sex-hormone binding globulin and albumin-bound testosterone. After dialysis, radioactivity was measured both inside and outside the tubing; the free testosterone results were expressed as a percentage of TT. The percentage measured [free / (free ϩ sex-hormone binding globulin bound)] was then multiplied by TT (measured by LC-MS/MS), and an absolute free testosterone value was obtained (20 ) . Our laboratory participates in the CDC Hormone Standardization Program, and based on the data, our values were accurate within Ϯ4% when Ͼ20 ng/dL but were within Ϯ20% when Ͻ20 ng/dL.
Androstenedione was also measured by LC-MS/MS (interassay CV was 10.2%, 6.1%, 5.0%, and 4.1% at 55, 3.8, 25.5, and 69.8 nmol/L, respectively). The assay for dehydroepiandrosterone sulfate (DHEA-S) was an automated competitive chemiluminescent immunoassay (IMMULITE 2000) with an interassay CV of 6% at concentrations of 2.0 mol/L, 3.6 mol/L, and 13.6 mol/L. Presence of at least 2:
• Oligo/anovulation
• Clinical or biochemical evidence of hyperandrogenism
• Polycystic ovary morphology on US
• Exclusion of other secondary diagnoses including APT Postmenopausal hyperandrogenism
• Postmenopausal status
• Includes ovarian hyperthecosis and IH (see below)
• Absence of APT APT Presence of at least 1:
• Radiologic image localizing a tumor
• Ovarian venous sampling localizing the source from 1 organ (1 adrenal or 1 ovary)
• Pathologic diagnosis of tumor
Ovarian hyperthecosis (34 )
Presence of at least one:
• Clinical diagnosis in the electronic health record Categorical variables were reported as percentages and analyzed with the Pearson 2 or Fisher exact test when applicable. Continuous variables were expressed as mean with SD when normally distributed and compared for group differences with the 2-sample t-test or ANOVA when Ͼ2 groups were compared. Continuous variables with a nongaussian distribution were reported as median with interquartile range (25th-75th quartiles) and analyzed with nonparametric testing (Wilcoxon rank-sum test). Because the reference interval for DHEA-S is established for specific age intervals, the percentage increase above the upper limit of the age-appropriate reference range was calculated for each participant and then compared by groups using nonparametric testing. A P value of Ͻ0.05 was considered significant. A ROC curve analysis was performed and used in determining the optimal threshold for the TT concentration to diagnose either an APT or postmenopausal pathologic hyperandrogenism. The thresholds on the ROC curve that provided the highest detection and prediction probabilities (sensitivity and specificity) were determined. Statistical analysis was performed using the JMP ® 10.0.0 (JMP, SAS Institute) statistical package. . Women with APT were significantly older than the PCOS group and younger than women with postmenopausal hyperandrogenism (APT vs PCOS, P Ͻ 0.01; APT vs postmenopausal hyperandrogenism, P ϭ 0.02; PCOS vs postmenopausal hyperandrogenism, P Ͻ 0.01). Women with APT presented significantly earlier after onset of symptoms and were more likely to have male-pattern alopecia than women with PCOS (see Table 1 in the Data Supplement that accompanies the online version of this article at http://www. clinchem.org/content/vol64/issue11).
Hormonal measurements. TT concentrations were significantly higher in the APT group than in women with PCOS or postmenopausal hyperandrogenism (see Table  1 in the online Data Supplement and Fig. 2A : APT vs PCOS, P Ͻ 0.01; APT vs postmenopausal hyperandrogenism, P Ͻ 0.01; and PCOS vs postmenopausal hyperandrogenism, P Ͻ 0.01). In addition, bioavailable testosterone ( Fig. 2B : APT vs PCOS, P Ͻ 0.01; APT vs postmenopausal hyperandrogenism, P ϭ 0.07; and PCOS vs APT, P ϭ 0.4) and free testosterone ( Fig. 2C : APT vs PCOS, P Ͻ 0.01; APT vs postmenopausal hyperandrogenism, P ϭ 0.02; and PCOS vs postmenopausal hyperandrogenism, P ϭ 0.2) were significantly higher in APT compared with PCOS and postmenopausal hyperandrogenism groups [measured in n ϭ 50 (56%) and n ϭ 47 (53%) individuals, respectively]. After ROC analysis, a TT concentration of Ն5.1 nmol/L had a sensitivity of 90% and a specificity of 81% for the diagnosis of APT (AUC, 0.90). DHEA-S concentrations were significantly higher in the PCOS group (see Table 1 in the online Data Supplement). However, after indexing increases in DHEA-S to age-specific ranges, there was no difference between groups. DHEA-S was mildly increased in 3 APT cases [1 adrenal tumor (7% above upper reference limit) and 2 ovarian tumors (4% and 19% above the upper reference limit)]. Androstenedione concentrations were available in only 26 (29%) cases. There was no statistical difference between groups in androstenedione or calculated TT/ androstenedione ratios (see Table 1 in the online Data Supplement). Of the 4 patients with adrenal APTs, androstenedione was measured in 3, with 2 of them having significantly increased androstenedione concentrations. The median TT/androstenedione ratio in patients with adrenal APT was 0.34 (n ϭ 3; range, 0.11-1.26), and in ovarian APT, it was 2.69 (n ϭ 6; range, 0.42-11.33). There was no statistical difference between the 2 groups, likely owing to limited numbers (P ϭ 0.06). DHEA-S was measured in 2 patients with adrenal APTs-1 was normal and the other increased.
Radiology and pathology. Eighty-one women underwent at least 1 imaging study with 18 (22%) identifying an APT. If imaging were performed only in women with a TT Ն5.1 nmol/L, 48 (60%; 40 PCOS and 8 postmenopausal hyperandrogenism) women without an underlying tumor would not have undergone imaging. Transabdominal or transvaginal ultrasonography (US) was the first radiologic test obtained in 75 (84%) women. This was followed by either computed tomography (CT) of the abdomen and pelvis (APT, 71%; postmenopausal hyperandrogenism, 63; PCOS, 19%; P Ͻ 0.01) or magnetic resonance imaging (MRI) of the abdomen and pelvis (APT, 24%; postmenopausal hyperandrogenism, 13%; PCOS, 4%; P Ͻ 0.01). The source of the APT was more frequently ovarian (81%, n ϭ 17) than adrenal (19%, n ϭ 4) ( Table 2) .
Imaging failed to identify the APT in 3 cases (all had US and MRI). All 3 women were postmenopausal and underwent bilateral oophorectomy with final pathology identifying ovarian tumors (Table 2 , cases 10, 20, and 21). Pelvic US failed to identify the APT in 4 of 16 cases (25%); CT scan failed to identify 2 of 15 (13%) tumors; and MRI did not identify any tumors that were not already identified by another imaging technique (Table 2) . Three women (1 premenopausal and 2 postmenopausal) required ovarian and adrenal vein sampling to diagnose an ovarian source.
POSTMENOPAUSAL WOMEN WITH SYMPTOMS OF HYPERANDROGENISM (SECOND COHORT)
Clinical characteristics. Seventy-one individuals (20 were in the first cohort) were included in the final analysis of the second cohort [36 idiopathic hyperandrogenism (IH) and 35 postmenopausal pathologic hyperandrogenism]. There were no statistically significant differences in age, ethnicity, frequency of symptoms of hyperandrogenism (acne, alopecia, or deepening of the voice), or duration of symptoms. Male-pattern alopecia and the distribution of terminal hair growth differed significantly between groups, being more severe in the postmenopausal pathologic hyperandrogenism group (see Table 2 in the online Data Supplement). were significantly higher in those with postmenopausal pathologic hyperandrogenism compared with the IH group (measured in 62% and 55% of patients, respectively). DHEA-S concentrations were not found to be different between groups [1.4 (0.7-2.8) vs 1.1 (0.8 -3.5) mol/L; P ϭ 0.7]. DHEA-S was significantly increased in adrenal APT (n ϭ 1; DHEA-S, 6.0 mol/L) compared with ovarian APTs (n ϭ 28; median, 1.4 mol/L; interquartile range, 0.77-2.49 mol/L). Interestingly, despite higher androstenedione concentrations [measured in 21 (30%) of patients] in the postmenopausal pathologic hyperandrogenism group, the TT/androstenedione ratio was also greater in the postmenopausal pathologic hyperandrogenism group (see Table 2 in the online Data Supplement). Luteinizing hormone and follicle-stimulating hormone concentrations were similar between the 2 groups. ROC analysis of TT concentrations revealed the most optimal diagnostic threshold was Ն2.2 nmol/L (sensitivity, 100%; specificity, 86%) for the diagnosis of postmenopausal pathologic hyperandrogenism (AUC, 0.95).
Radiology and pathology. Forty-four (62%) women in the postmenopausal cohort with symptoms of hyperandrogenism underwent radiological investigation [25% (n ϭ 9) in the IH group and 100% (n ϭ 35) in the postmenopausal pathologic hyperandrogenism group]. Most women in the postmenopausal pathologic hyperandrogenism group received pelvic US as their first radiological investigation (94% vs 17%; P Ͻ 0.01), followed by CT scan (60% vs 11%; P Ͻ 0.01) and MRI scan (23% vs 3%; P ϭ 0.01). The source of pathologic hyperandrogenism was largely ovarian (97%; n ϭ 34) with only 1 woman's source being adrenal (2.2 cm right adrenal adenoma on pathology) (Table 3) . Of the 35 individuals in the postmenopausal pathologic hyperandrogenism group, 20 (57%) had a clinical or pathological diagnosis of ovarian hyperthecosis, and 15 (43%) met the criteria for an APT. Of those with a diagnosis of ovarian hyperthecosis, median ovarian volumes on pelvic US were 4.3 mL (range, 3.0 -4.8 mL) on the right and 5.3 mL (range, 2.0 -12 mL) on the left. Pelvic US identified 53% (n ϭ 8) of ovarian APT. CT scan identified 1 additional tumor when pelvic US failed to do so. There was pathological confirmation of an APT in 12 women. Eleven (92%) had an ovarian tumor and 1 (8%) had an adrenal tumor. In those without imaging or pathologic abnormality (n ϭ 6), postoperative testosterone concentrations after bilateral oophorectomy were all within the normal range with resolution of hyperandrogenism symptoms at follow-up evaluation.
Discussion
APTs have been previously described as having a rapid onset of virilizing symptoms with increased TT concentrations Ͼ6.9 nmol/L by RIA (21, 22 ) . The results of our study show that when measured by LC-MS/MS, TT of Ն5.1 nmol/L was the most discriminatory diagnostic threshold for the diagnosis of APT in women with severe biochemical hyperandrogenemia (defined as TT Ն3.5 nmol/L). In postmenopausal women presenting with symptoms of hyperandrogenism, however, we found that a lower diagnostic threshold for TT (Ն2.2 nmol/L) optimally identified postmenopausal pathologic hyperandrogenism (APT and ovarian hyperthecosis). Given the predicted shift of all TT measurements to LC-MS/MS in women (15 ) and the recent updated recommendation by the Endocrine Society to measure TT in all women with hirsutism (2 ), these results provide an important update to clinical practice. To our knowledge, this is the first study using LC-MS/MS to characterize TT diagnostic thresholds for APT in women with hyperandrogenemia and for pathologic hyperandrogenism in postmenopausal women. Previous studies evaluating the optimal diagnostic threshold for TT concentrations to identify APTs used less accurate methods for measuring TT in women. Derksen et al. (23 ) used RIA in 100 women with androgen excess (27 with virilizing adrenal tumors and 73 with nonneoplastic hirsutism) and proposed a higher diagnostic threshold (TT Ն6.9 nmol/L; sensitivity, 100%; specificity, 50%). However, their cohort comprised adrenocortical carcinoma, including those with cosecretion of cortisol, as the majority of virilizing tumors (12 of 14). We excluded adrenocortical carcinoma and Cushing's syndrome, as the clinical picture often differs, with the diagnostic evaluation guided by the Cushing's diagnosis. In addition, Yance et al. (24 ) suggested a significantly higher TT concentration of Ͼ10.8 nmol/L (sensitivity, 76.9%; specificity, 90.5%) to differentiate ovarian APT from ovarian hyperthecosis. However, their approach has several limitations in applicability to clinical practice. The immunofluorometric assay used to measure TT concentrations is subject to increased variability, and results differ depending on the method of collection (25 ) . Application of a diagnostic threshold of Ն6.9 nmol/L in our cohort would have resulted in 6 missed cases of APT and 22 missed cases of postmenopausal pathologic hyperandrogenism. This supports our hypothesis that the LC-MS/MS diagnostic threshold for APT would need to be lower than RIA based on previous data that RIA overestimates TT concentrations in women (10, 11, 26 ) .
Kaltas et al. (27 ) showed that once adrenocortical carcinoma is excluded, an ovarian tumor is the most common cause of an APT, which is consistent with our results (81% ovarian origin). This is an important distinction from other cohorts, in which adrenocortical carcinoma with or without Cushing's comprised Ͼ59% of cases of hyperandrogenemic patients (23, 28 ) . Therefore, pelvic imaging should be considered as the first step after biochemical confirmation of severe hyperandrogenemia, especially if the clinical picture does not suggest hypercortisolism. Once an adrenal source has been excluded, the evaluation should focus on localization of an ovarian source and/or consideration of bilateral oophorectomy in postmenopausal women.
POSTMENOPAUSAL HYPERANDROGENISM
Severe androgen excess in women can lead to significant psychosocial distress (29 ) , decreased quality of life (30 ), (32, 33 ) , and endometrial adenocarcinoma in postmenopausal women (34 ) . Therefore, the benefits of surgical intervention for postmenopausal women with ovarian hyperthecosis or APT often outweigh the risks (35 ) . Thus, we combined both ovarian hyperthecosis and APT groups for postmenopausal women as a meaningful diagnostic category for decisionmaking about further diagnostic testing and possible surgical intervention. To our knowledge, we are the first to demonstrate with any assay that the diagnostic threshold for pathologic hyperandrogenism in postmenopausal women should be lower (TT Ն2.2 nmol/L) to ensure inclusion of clinically significant ovarian hyperthecosis. Because this threshold is close to the upper limit of normal, this suggests that the normal reference range for TT should be redefined for menopausal women. The diagnostic criteria for ovarian hyperthecosis are yet to be clearly defined. Although the gold standard is a histological diagnosis with nests of steroidogenically active luteinized stromal cells throughout the ovarian stroma (36 ), other definitions include postmenopausal status with symptoms of hyperandrogenism (33 ), TT Ն5.2 nmol/L (8 ), and US findings of bilateral enlarged ovaries (37 ) . Ovarian hyperthecosis cases have also been described with normal ovarian volume (37 ) and histology (37) (38) (39) . Immunohistochemistry in reported cases with normal histology has revealed the presence of P450c17␣-positive cells, indicating persistence of steroidogenic luteinizing hormone-responsive cells in postmenopausal women (38, 39 ) . The clinical diagnosis of ovarian hyperthecosis was assigned in our cohort despite normal imaging and ovarian pathology in 45% of cases (see the online Data Supplement). Consistent with previous reports (24 ) , ovarian volume was increased in some but not all individuals in the ovarian hyperthecosis group (7 of 20 in our cohort and 8 of 21 in the previously reported cohort) (24 ) . This highlights the limitation of histologic and radiologic diagnosis of ovarian hyperthecosis. The clinical diagnosis of ovarian hyperthecosis identified women who responded to medical or surgical therapy, confirming the ovarian source of hyperandrogenism.
STRENGTHS AND LIMITATIONS
Our study has several strengths, including the use of LC-MS/MS (gold standard) for all testosterone measurements and a thorough systematic search of the Mayo Clinic laboratory and clinical electronic health record, which had a high volume of exclusive LC-MS/MS TT measurements in Ͼ14000 women during the specified period. This cohort also includes the greatest number of ovarian APTs to date. As a retrospective review, this study might have missed cases of APT at an even lower TT concentration in premenopausal women if the evaluating provider did not order a TT. However, a separate confirmatory search was performed for APT, and there were no cases of APT below a TT concentration of 3.5 nmol/L. Because of the tertiary care practice at the Mayo Clinic, some diagnosed APT and ovarian hyperthecosis cases were not resected or managed clinically at our center. As a result, some patients were lost to follow-up [36 (22.5%) patients in both cohorts combined (1 woman in the APT group, 6 women in the postmenopausal pathologic hyperandrogenism group)], and not all cases had pathologic confirmation. However, any misclassification between ovarian hyperthecosis and APT would still include the woman in the appropriate group-postmenopausal pathologic hyperandrogenism-the clinically relevant group to identify with a diagnostic threshold for further evaluation, treatment, and/or surgery. In addition, other biochemical markers of hyperandrogenemia (bioavailable testosterone, free testosterone, DHEA-S, and androstenedione) were not measured in all patients. Given the rarity of postmenopausal pathologic hyperandrogenism, 20 women were included in both cohorts. These findings would be strengthened by future confirmatory studies utilizing larger cohorts.
Conclusion
Using LC-MS/MS measurements of TT serum concentrations in women, the optimal screening threshold to diagnose APT was a TT of Ն5.1 nmol/L. To our knowledge, this is also the first study to describe a TT diagnostic threshold for postmenopausal pathologic hyperandrogenism derived from a postmenopausal cohort. We demonstrated that a lower threshold (TT Ն2.2 nmol/L) identifies symptomatic postmenopausal women who should have further detailed imaging evaluation for postmenopausal pathologic hyperandrogenism that could be cured with surgical intervention rather than medications. Clinical history appeared to be of limited use in identifying women with APT or postmenopausal pathologic hyperandrogenism. A. Sharma, designed the project, performed chart review and data collection, analyzed the data and wrote the manuscript, critically reviewed and edited the manuscript; E. Kapoor, designed the project, performed chart review and data collection, critically reviewed and edited the manuscript; R. Singh, designed the project, validated the laboratory measurements, critically reviewed and edited the manuscript; A.
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